XML 125 R31.htm IDEA: XBRL DOCUMENT v3.20.4
Grant Revenue (Tables)
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
The following tables summarize grant revenue and deferred grant revenue for and as of the periods presented (in thousands):

Years Ended
202020192018
BARDA$521,652 $7,608 $6,736 
Other grant revenue7,253 4,565 5,820 
Total grant revenue$528,905 $12,173 $12,556 


December 31,
20202019
Deferred grant revenue$5,261 $2,777 
The following table summarizes our total consolidated net revenue from our strategic collaborators for the periods presented (in thousands):

Years Ended December 31,
Collaboration Revenue by Strategic Collaborator:20202019
2018 (1)
Merck$26,076 $36,608 $66,082 
AstraZeneca32,624 5,233 45,993 
Vertex15,505 6,195 10,437 
Other413 — — 
Total collaboration revenue$74,618 $48,036 $122,512 

________
(1) Under ASC 605
The following table summarizes the revenue recognized for the periods presented (in thousands):

Years Ended December 31,
202020192018
Combined AZ Agreements$18,371 $4,650 $45,393 
The following table summarizes the revenue and contra-revenue recognized for the periods presented (in thousands):
Years Ended December 31,
202020192018
Contra-revenue under the May 2019 Amendment$(7,088)$(5,265)$— 
Collaboration revenue under the 2015 Merck Agreement62 492 24,582 
Total contra-revenue$(7,026)$(4,773)$24,582